Pediatric preclinical testing consortium evaluation of the EZH2 inhibitor tazemetostat in orthotopic PDX models of pediatric brain tumors.

被引：1
|
作者：
Li, Xiao-Nan
Qi, Lin
Kogiso, Mari
Lindsay, Holly Brianne
Erickson, Stephen W.
Guo, Yuelong
Smith, Malcolm A.
Teicher, Beverly A.
机构：
[1] Baylor Coll Med, Program Preclin Neuro Oncol Res, Texas Childrens Canc Ctr, Lab Mol Neuro Oncol, Houston, TX 77030 USA
[2] Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA
[3] RTI Int, Res Triangle Pk, NC USA
[4] NCI, Canc Therapy Evaluat Program, Washington, DC USA
[5] NIH, NCI, Bldg 10, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.10551
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10551
引用
收藏
页数：1
相关论文
共 50 条
  • [31] THERAPEUTIC TARGETING OF EZH2 AND BET BRD4 IN PEDIATRIC RHABDOID TUMORS
    Ishi, Yukitomo
    Zhang, Yongzhan
    Zhang, Ali
    Sasaki, Takahiro
    Piunti, Andrea
    Suri, Amreena
    Watanabe, Jun
    Abe, Kouki
    Natsumeda, Manabu
    Zou, Lihua
    Shilatifard, Ali
    Hashizume, Rintaro
    NEURO-ONCOLOGY, 2022, 24 : 228 - 228
  • [32] Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors
    Ishi, Yukitomo
    Zhang, Yongzhan
    Zhang, Ali
    Sasaki, Takahiro
    Piunti, Andrea
    Suri, Amreena
    Watanabe, Jun
    Abe, Kouki
    He, Xingyao
    Katagi, Hiroaki
    Bhalla, Pankaj
    Natsumeda, Manabu
    Zou, Lihua
    Shilatifard, Ali
    Hashizume, Rintaro
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (05) : 715 - 726
  • [33] Preclinical evaluation of trastuzumab deruxtecan (T-DXd; DS-8201a), a HER2 antibody-drug conjugate, in pediatric solid tumors by the Pediatric Preclinical Testing Consortium (PPTC)
    Hingorani, Pooja
    Zhang, Wendong
    Kurmasheva, Raushan
    Zhang, Zhongting
    Wang, Yifei
    Xu, Zhaohui
    Roth, Michael
    Gill, Jonathan
    Harrison, Douglas
    Erickson, Stephen
    Kolb, Edward A.
    Smith, Malcolm
    Houghton, Peter
    Gorlick, Richard
    CANCER RESEARCH, 2020, 80 (16)
  • [34] Regorafenib antitumor activity alone and in combination with radio or chemotherapy in preclinical models of pediatric solid tumors.
    Daudigeos-Dubus, Estelle
    Le Dret, Ludivine
    Lanvers-Kaminsky, Claudia
    Bawa, Olivia
    Opolon, Paule
    Villa, Irene
    Bosq, Jacques
    Vassal, Gilles
    Zopf, Dieter
    Geoerger, Birgit
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [35] Pediatric preclinical testing program (PPTP) evaluation of the EGFR and ErbB2 inhibitor lapatinib
    Houghton, Peter J.
    Maris, John M.
    Courtright, Joshua
    Friedman, Henry S.
    Keir, Stephen T.
    Lock, Richard B.
    Carol, Hernan
    Gorlick, Richard
    Kolb, E. Anders
    Keshelava, Nino
    Reynolds, C. Patrick
    Morton, Christopher L.
    Smith, Malcolm A.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3471S - 3471S
  • [36] ROLE OF POLYCOMB PROTEINS EZH2 AND BMI-1 IN PATHOGENESIS OF PEDIATRIC SOLID TUMORS
    D'Angelo, Velia
    Ramaglia, Maria
    Iannotta, Adriana
    Perrotta, Silverio
    Ficociello, Carmine
    Bottigliero, Gaetano
    Pota, Elvira
    Savarese, Raffaele
    Affinita, Maria Carmen
    Di Pinto, Daniela
    Pecoraro, Giulia
    Fiano, Paola
    Indolfi, Cristiana
    Casale, Fiorina
    Indolfi, Paolo
    PEDIATRIC BLOOD & CANCER, 2012, 59 (06) : 1065 - 1065
  • [37] Preclinical effect of selinexor (KPT-330), a selective inhibitor of nuclear export, in pediatric rhabdoid tumors.
    Marks, Lianna Jean
    Diolaiti, Daniel
    Mundi, Prabhjot Singh
    Gaviria, Ervin
    Rainey, Allison
    Dela Cruz, Filemon
    Califano, Andrea
    Kung, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] PHARMACOLOGICAL EFFECT OF EZH2 INHIBITOR IN PEDIATRIC T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA
    Iannotta, A.
    Ramaglia, M.
    Lombardi, A.
    D'Angelo, V.
    Caraglia, M.
    Affinita, M. C.
    Fusco, C.
    Di Martino, M.
    Di Pinto, D.
    Oreste, M.
    Indolfi, C.
    Indolfi, P.
    Casale, F.
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S258 - S259
  • [39] Impact of SCID mouse gender on tumorigenicity, xenograft growth and drug-response in a large panel of orthotopic PDX models of pediatric brain tumors
    Qi, Lin
    Kogiso, Mari
    Du, Yuchen
    Zhang, Huiyuan
    Braun, Frank K.
    Huang, Yulun
    Teo, Wan-Yee
    Lindsay, Holly
    Zhao, Sibo
    Baxter, Patricia
    Zhao, Xiumei
    Yu, Litian
    Liu, Zhigang
    Zhang, Xingding
    Su, Jack M. F.
    Adesina, Adekunle
    Yang, Jianhua
    Chintagumpala, Murali
    Perlaky, Laszlo
    Man, Chris Tsz-Kwong
    Lau, Ching C.
    Li, Xiao-Nan
    CANCER LETTERS, 2020, 493 : 197 - 206
  • [40] MOLECULAR CHARACTERIZATION OF ORTHOTOPIC PATIENT-DERIVED XENOGRAFT MODELS OF PEDIATRIC BRAIN TUMORS
    Brabetz, Sebastian
    Groebner, Susanne N.
    Seker-Cin, Huriye
    Mack, Norman L.
    Hovestadt, Volker
    Jones, David T. W.
    Selt, Florian
    Milde, Till
    Wise, Madison T.
    Rusert, Jessica M.
    Pedro, Kyle
    Bloom, Karina
    Witt, Olaf
    Leary, Sarah E.
    Li, Xiao-Nan
    Wechsler-Reya, Robert J.
    Olson, James M.
    Pfister, Stefan M.
    Kool, Marcel
    NEURO-ONCOLOGY, 2016, 18 : 142 - 142
12345